News on clinical chemistry systems and applications.
The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.
Molecular diagnostics revenues rose 5 percent driven in part by growth in infectious disease testing, a core area of diagnostic market focus for the firm.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.
